We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

26 hedge funds and large institutions have $12.4M invested in Cymabay Therapeutics in 2016 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

2% more capital invested

Capital invested by funds: $12.1M → $12.4M (+$298K)

13% less funds holding

Funds holding: 30 → 26 (-4)

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

Holders
26
Holders Change
-4
Holders Change %
-13.33%
% of All Funds
0.69%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.08%
New
4
Increased
6
Reduced
5
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$130K
2
UCFA
United Capital Financial Advisors
Texas
+$53.8K
3
Renaissance Technologies
Renaissance Technologies
New York
+$35.9K
4
Citadel Advisors
Citadel Advisors
Florida
+$33.3K
5
BFA
BlackRock Fund Advisors
California
+$33.3K

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$1.62M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.14M
3
JGC
J. Goldman & Co
New York
-$323K
4
LOAMU
Lombard Odier Asset Management (USA)
New York
-$117K
5
SM
Sabby Management
Florida
-$91K
Name Holding Trade Value Shares
Change 		Change in
Stake
PVI
26
Pura Vida Investments
New York
– -$76K -56,000 Closed
TRCT
27
Tower Research Capital (TRC)
New York
– -$8K -5,777 Closed
Bank of America
28
Bank of America
North Carolina
– -$4.41K -2,124 -97%
Barclays
29
Barclays
United Kingdom
– -$1K -1,300 Closed
JP Morgan Chase
30
JP Morgan Chase
New York
– +$207 +100 New
1
2

CBAY Hedge Fund Activity: Q2 2016 in Review

26 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q2 2016, worth a combined $12.4M — up 2.5% from $12.1M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of CBAY and 4 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 6 added.

The largest buyer was Vanguard Group, adding an estimated $130K. The largest seller was Adage Capital Partners, cutting an estimated $1.62M.

  • 26 institutional investors held Cymabay Therapeutics (CBAY) as of Q2 2016, down from 30 in Q1 2016.
  • Funds reported $12.4M of Cymabay Therapeutics stock for Q2 2016, up 2.5% quarter-over-quarter.
  • 4 funds opened new Cymabay Therapeutics positions in Q2 2016 and 7 closed out, a net change of -3 holders.
  • The largest Cymabay Therapeutics buyer in Q2 2016 was Vanguard Group, an estimated $130K added.
  • The largest Cymabay Therapeutics seller in Q2 2016 was Adage Capital Partners, an estimated $1.62M sold.

Based on aggregated 13F filings for Q2 2016.